We are live on ! Find out more
PJP icon

Invesco Pharmaceuticals ETF

91 hedge funds and large institutions have $85.3M invested in Invesco Pharmaceuticals ETF in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 31 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.67% more ownership

Funds ownership: 17.18%17.85% (+0.67%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

5% less funds holding

Funds holding: 9691 (-5)

15% less capital invested

Capital invested by funds: $101M → $85.3M (-$15.6M)

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

35% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 31

Holders
91
Holders Change
-5
Holders Change %
-5.21%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
14
Increased
20
Reduced
31
Closed
17
Calls
$256K
Puts
Net Calls
+$256K
Net Calls Change
-$23K

PJP Hedge Fund Activity: Q4 2018 in Review

91 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q4 2018, worth a combined $85.3M — down 15% from $101M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of PJP and 14 opened new positions — a net loss of 3 holders — while 31 trimmed existing stakes and 20 added.

The largest buyer was Morgan Stanley, adding an estimated $4.26M. The largest seller was UBS Group, cutting an estimated $3.26M.

  • 91 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q4 2018, down from 96 in Q3 2018.
  • Funds reported $85.3M of Invesco Pharmaceuticals ETF stock for Q4 2018, down 15% quarter-over-quarter.
  • 14 funds opened new Invesco Pharmaceuticals ETF positions in Q4 2018 and 17 closed out, a net change of -3 holders.
  • The largest Invesco Pharmaceuticals ETF buyer in Q4 2018 was Morgan Stanley, an estimated $4.26M added.
  • The largest Invesco Pharmaceuticals ETF seller in Q4 2018 was UBS Group, an estimated $3.26M sold.

Based on aggregated 13F filings for Q4 2018.